Delving into the Latest Updates on Votucalis with Synapse

Overview

Basic Info

Drug Type

Recombinant protein

Synonyms

Target

Mechanism

H1 receptor antagonists(Histamine H1 receptor antagonists), H2 receptor antagonists(Histamine H2 receptor antagonists), H4 receptor antagonists(Histamine H4 receptor antagonists)

Therapeutic Areas

Nervous System DiseasesSkin and Musculoskeletal Diseases

Active Indication

PainPruritus

Inactive Indication

CataractConjunctivitis, AllergicOcular inflammation+ [3]

Originator Organization

Evolutec Group Plc

Active Organization

Akari Therapeutics Plc

Inactive Organization

Evolutec Group Plc

Drug Highest PhasePhase 3

First Approval Date-

Regulation-

Login to view timeline

Gene Sequence

Sequence Code 25901528

Source: *****

The purpose of this study is to evaluate the safety and effectiveness of three concentrations of rEV131, a new investigational anti-inflammatory agent, compared to placebo (an inactive substance) and an FDA approved anti-inflammatory agent in patients with ocular inflammation who have undergone cataract extraction with intra-ocular lens implantation.

Start Date-

Sponsor / Collaborator

Evolutec Group Plc

NCT00247520 / Unknown statusPhase 1/2

Two Center Evaluation of the Safety and Efficacy of Topical Nasal rEV131 Versus rEV131 Vehicle (Placebo)in the Prevention of the Signs and Symptoms of Allergic Rhinitis Induced by Nasal Allergen Challenge

The purpose of this study is to see whether rEV131 when given as a nasal spray in a single dose to each nostril is safe and can reduce the signs and symptoms of allergic rhinitis (hay fever) caused by an allergen challenge. All patients enrolled will be known to be allergic to ragweed pollen and will be given ragweed pollen extract in both nostrils 30 minutes after either rEV131 or innactive vehicle (placebo). The signs and symptoms (sneezing, itching, stuffiness and runny nose) will each be given a score from 0 to 3 by the patient and these will be added together and the combined scores from patients treated with rEV131 will be compared with those who received placebo.

Start Date01 May 2005

Sponsor / Collaborator

Evolutec Group Plc

100 Clinical Results associated with Votucalis

Login to view more data

100 Translational Medicine associated with Votucalis

Login to view more data

100 Patents (Medical) associated with Votucalis

Login to view more data

4

Literatures (Medical) associated with Votucalis

01 Nov 2005·Annals of the New York Academy of SciencesQ2 · CROSS-FIELD

Histamine Scavenging Attenuates Endotoxin‐Induced Acute Lung Injury

Q2 · CROSS-FIELD

Article

Author: Patricia Nuttall ; Guido C. Paesen ; Bernhard Ryffel ; Bruno Schnyder ; Isabelle Maillet ; Isabelle Couillin ; Wynne Weston-Davies

Histamine is an important mediator of early and late inflammatory responses. Here we asked whether scavenging of endogenous histamine by the arthropod‐derived histamine binding protein EV131 diminishes acute respiratory distress syndrome (ARDS) induced by inhaled endotoxin. We demonstrate that EV131 (360 μg given intranasally) reduced endotoxin‐induced bronchoconstriction and recruitment of neutrophils. Furthermore, EV131 administration diminished TNF‐α and protein leak in the bronchoalveolar lavage fluid. The data suggest that histamine attenuates endotoxin‐induced bronchoconstriction and neutrophil recruitment. Therefore, scavenging of histamine by EV131 may represent a novel therapeutic strategy in ARDS.

01 Nov 2005·Annals of the New York Academy of SciencesQ2 · CROSS-FIELD

Arthropod‐Derived Protein EV131 Inhibits Histamine Action and Allergic Asthma

Q2 · CROSS-FIELD

Article

Author: Patricia Nuttall ; Olga Lissina ; Bernhard Ryffel ; Rene Moser ; Wynne Weston-Davies ; Silvia Schnyder ; Bruno Schnyder ; Isabelle Couillin ; Guido C. Paesen

Histamine is an important mediator of allergic responses. Arthropods express several biologically active proteins in their saliva, which may allow a prolonged blood meal on the host. Proteins identified and expressed include histamine, serotonin, tryptase, and complement binding proteins. We review here data that scavenging of endogenous histamine by the histamine‐binding protein EV131 has a profound inhibitory effect on allergic asthma. Aerosol administration of EV131 prevented airway hyperreactivity and abrogated peribronchial inflammation, eosinophil recruitment, mucus hypersecretion, and IL‐4 and IL‐5 secretion. Saturation with histamine abrogated the inhibitory effect of EV131 on bronchial hyperreactivity. The data suggest that histamine plays a role in allergies and that scavenging of histamine by EV131 may represent a novel therapeutic strategy in the treatment of allergic diseases.

01 Sep 2004·The Journal of ImmunologyQ2 · MEDICINE

Arthropod-Derived Histamine-Binding Protein Prevents Murine Allergic Asthma

Q2 · MEDICINE

Article

Author: Nuttall, Patricia A. ; Paesen, Guido C. ; Vargaftig, B. Boris ; Moser, René ; Lefort, Jean ; Ryffel, Bernhard ; Jacobs, Muazzam ; Maillet, Isabelle ; Couillin, Isabelle ; Weston-Davies, Wynne

AbstractBecause histamine receptor type I blockade attenuates allergic asthma, we asked whether complete neutralization of histamine by an arthropod-derived, high affinity histamine-binding protein (EV131) would prevent allergic asthma. Intranasal administration of EV131 given before Ag challenge in immunized mice prevented airway hyperreactivity by 70%, and abrogated peribronchial inflammation, pulmonary eosinophilia, mucus hypersecretion, and IL-4 and IL-5 secretion. Saturation with histamine abrogated the inhibitory effect of EV131 on bronchial hyperreactivity. The inhibitory effect of EV131 on bronchial hyperreactivity was comparable to that of glucocorticosteroids. These results demonstrate that histamine is a critical mediator of allergic asthma. Therefore, complete neutralization of histamine, rather than specific histamine receptor blockade, may have a profound effect on allergic asthma.

100 Deals associated with Votucalis

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB05032

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Pain	Phase 3	US	Akari Therapeutics Plc	-
Pruritus	Phase 3	US	Akari Therapeutics Plc	-
Cataract	Phase 2	US	Evolutec Group Plc	19 Jul 2006
Ocular inflammation	Phase 2	US	Evolutec Group Plc	19 Jul 2006
Rhinitis, Allergic, Seasonal	Phase 2	US	Evolutec Group Plc	01 May 2005
Conjunctivitis, Allergic	Preclinical	-	Evolutec Group Plc	-
Post procedural inflammation	Preclinical	-	Evolutec Group Plc	-
Rhinitis, Allergic	Discovery	-	Evolutec Group Plc	-